ahlam1399
07-15-2016, 07:31 AM
UK charity pockets $150 million from Merck cancer immu**therapy drug
LONDON (Reuters) - British medical charity MRC Tech**logy has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda, allowing it to plough fresh funds into new research.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=XwbtDuW7dSg:T78YH9Vvo8A:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=XwbtDuW7dSg:T78YH9Vvo8A:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=XwbtDuW7dSg:T78YH9Vvo8A:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=XwbtDuW7dSg:T78YH9Vvo8A:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=XwbtDuW7dSg:T78YH9Vvo8A:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/XwbtDuW7dSg
LONDON (Reuters) - British medical charity MRC Tech**logy has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda, allowing it to plough fresh funds into new research.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=XwbtDuW7dSg:T78YH9Vvo8A:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=XwbtDuW7dSg:T78YH9Vvo8A:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=XwbtDuW7dSg:T78YH9Vvo8A:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=XwbtDuW7dSg:T78YH9Vvo8A:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=XwbtDuW7dSg:T78YH9Vvo8A:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/XwbtDuW7dSg